Literature DB >> 24039054

Severe congenital lipodystrophy and a progeroid appearance: Mutation in the penultimate exon of FBN1 causing a recognizable phenotype.

Toshiki Takenouchi1, Mariko Hida, Yoshiaki Sakamoto, Chiharu Torii, Rika Kosaki, Takao Takahashi, Kenjiro Kosaki.   

Abstract

Recently, three marfanoid patients with congenital lipodystrophy and a neonatal progeroid appearance were reported. Although their phenotype was distinct from that of classic Marfan syndrome, they all had a truncating mutation in the penultimate exon, i.e., exon 64, of FBN1, the causative gene for Marfan syndrome. These patients might represent a new entity, but the exact phenotypic and genotypic spectrum remains unknown. Here, we report on a girl born prematurely who exhibited severe congenital lipodystrophy and a neonatal progeroid appearance. The patient exhibited a characteristic growth pattern consisting of an accelerated growth in height with a discrepant poor weight gain. She had a characteristic facial appearance with craniosynostosis. A mutation analysis identified c.8175_8182del8bp, p.Arg2726Glufs*9 in exon 64 of the FBN1 gene. A review of similar, recently reported patients revealed that the cardinal features of these patients include (1) congenital lipodystrophy, (2) premature birth with an accelerated linear growth disproportionate to the weight gain, and (3) a progeroid appearance with distinct facial features. Lines of molecular evidence suggested that this new progeroid syndrome represents a neomorphic phenotype caused by truncated transcripts with an extremely charged protein motif that escapes from nonsense-mediated mRNA decay, altering FBN1-TGF beta signaling, rather than representing the severe end of the hypomorphic phenotype of the FBN1-TGF beta disorder spectrum. We propose that this marfanoid entity comprised of congenital lipodystrophy, a neonatal progeroid appearance, and a peculiar growth profile and caused by rare mutations in the penultimate exon of FBN1, be newly referred to as marfanoid-progeroid syndrome.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  Marfan syndrome; congenital lipodystrophy; progeroid appearance

Mesh:

Substances:

Year:  2013        PMID: 24039054     DOI: 10.1002/ajmg.a.36157

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  16 in total

Review 1.  Marfanoid-progeroid-lipodystrophy syndrome: a newly recognized fibrillinopathy.

Authors:  Eberhard Passarge; Peter N Robinson; Luitgard M Graul-Neumann
Journal:  Eur J Hum Genet       Date:  2016-02-10       Impact factor: 4.246

Review 2.  Phenotypic and Genetic Characteristics of Lipodystrophy: Pathophysiology, Metabolic Abnormalities, and Comorbidities.

Authors:  Baris Akinci; Rasimcan Meral; Elif Arioglu Oral
Journal:  Curr Diab Rep       Date:  2018-11-08       Impact factor: 4.810

3.  Bi-allelic POLR3A Loss-of-Function Variants Cause Autosomal-Recessive Wiedemann-Rautenstrauch Syndrome.

Authors:  Jennifer A Wambach; Daniel J Wegner; Nivedita Patni; Martin Kircher; Marcia C Willing; Dustin Baldridge; Chao Xing; Anil K Agarwal; Samantha A Schrier Vergano; Chirag Patel; Dorothy K Grange; Amy Kenney; Tasnim Najaf; Deborah A Nickerson; Michael J Bamshad; F Sessions Cole; Abhimanyu Garg
Journal:  Am J Hum Genet       Date:  2018-11-07       Impact factor: 11.025

4.  Asprosin, a Fasting-Induced Glucogenic Protein Hormone.

Authors:  Chase Romere; Clemens Duerrschmid; Juan Bournat; Petra Constable; Mahim Jain; Fan Xia; Pradip K Saha; Maria Del Solar; Bokai Zhu; Brian York; Poonam Sarkar; David A Rendon; M Waleed Gaber; Scott A LeMaire; Joseph S Coselli; Dianna M Milewicz; V Reid Sutton; Nancy F Butte; David D Moore; Atul R Chopra
Journal:  Cell       Date:  2016-04-14       Impact factor: 41.582

5.  The use of next-generation sequencing in molecular diagnosis of neurofibromatosis type 1: a validation study.

Authors:  Ryo Maruoka; Toshiki Takenouchi; Chiharu Torii; Atsushi Shimizu; Kumiko Misu; Koichiro Higasa; Fumihiko Matsuda; Arihito Ota; Katsumi Tanito; Akira Kuramochi; Yoshimi Arima; Fujio Otsuka; Yuichi Yoshida; Keiji Moriyama; Michihito Niimura; Hideyuki Saya; Kenjiro Kosaki
Journal:  Genet Test Mol Biomarkers       Date:  2014-10-17

Review 6.  Asprosin, a C-Terminal Cleavage Product of Fibrillin 1 Encoded by the FBN1 Gene, in Health and Disease.

Authors:  Mehmet Akif Ovali; Ibrahim Bozgeyik
Journal:  Mol Syndromol       Date:  2022-02-08

Review 7.  Energy Regulation Mechanism and Therapeutic Potential of Asprosin.

Authors:  Jennifer G Hoffmann; Wei Xie; Atul R Chopra
Journal:  Diabetes       Date:  2020-04       Impact factor: 9.461

Review 8.  What lipodystrophies teach us about the metabolic syndrome.

Authors:  Jake P Mann; David B Savage
Journal:  J Clin Invest       Date:  2019-08-05       Impact factor: 14.808

9.  Identification of fibrillin 1 gene mutations in patients with bicuspid aortic valve (BAV) without Marfan syndrome.

Authors:  Guglielmina Pepe; Stefano Nistri; Betti Giusti; Elena Sticchi; Monica Attanasio; Cristina Porciani; Rosanna Abbate; Robert O Bonow; Magdi Yacoub; Gian Franco Gensini
Journal:  BMC Med Genet       Date:  2014-02-24       Impact factor: 2.103

10.  C-terminal propeptide is required for fibrillin-1 secretion and blocks premature assembly through linkage to domains cbEGF41-43.

Authors:  Sacha A Jensen; Georgia Aspinall; Penny A Handford
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-30       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.